Labiotech.eu

News and Trends 14 Jul 2016

French Biotech that makes Drugs faster and cheaper IPO’s for €31M

Pharnext has successfully completed its IPO on the Euronext Paris exchange, allowing it to move forward with Phase II and III trials for Neurological diseases that include Alzheimer’s. Based in Paris, Pharnext is developing new therapies for neurological conditions, including rare diseases such as Charcot-Marie-Tooth Disease. New partners to join this biotech in the €31M IPO include Galapagos […]

July 14, 2016 - 2 minutesmins - By Dani Bancroft

News and Trends 13 Jul 2016

French Pharma licenses California PD-1 Cancer Antibody for €710M

San Diego’s Sorrento Therapeutics has bagged a quarter-billion euro deal with Servier. The French Pharma giant will develop Sorrento’s PD-1 targeting platform – a key checkpoint inhibitor in Immuno-Oncology. Sorrento’s proprietary G-MAB library platform was used to identify and generate STI-A1110, an antibody which targets PD-1, one of the key targets in the rapidly developing immuno-oncology therapy […]

July 13, 2016 - 2 minutesmins - By Dani Bancroft

News and Trends 13 Jul 2016

Europe’s most valuable Biotech just launched 2 new Trials

Within a week, Actelion has announced both Phase II and III trial studies for insomnia and hypertension in children. Even for Europe’s most valuable biotech, this is an impressive period. Actelion is to enter Phase II clinical development with new dual orexin receptor antagonist in patients with insomnia. The day before this, it also announced a […]

July 13, 2016 - 3 minutesmins - By Dani Bancroft

News and Trends 12 Jul 2016

Unique Natural Killer T-Cell Therapy secures €282M in Japan Deal

Belgian Celyad granted an exclusive license to Osaka based ONO Pharmaceutical for the development and commercialisation of Celyad’s unique allogeneic cell therapy in Japan, Korea and Taiwan. This license agreement opens new markets to Celyad and its NKR-2 T-cell cancer immunotherapy. In addition to a deal worth up to €282M, Celyad will also receive double digit royalties based on […]

July 12, 2016 - 3 minutesmins - By Dani Bancroft

News and Trends 12 Jul 2016

How did Helen Lee overcome barriers to HIV Diagnostics in the ‘Real World’?

How can diagnostics be improved in resource limited settings? And how can the practical limitations of transporting heat-sensitive assay material through hot climates be overcome? The University of Cambridge’s Dr Helen Lee won this year’s ‘Popular Choice’ Award, at the European Patent Office (EPO) awards. The winner of this prize category is selected from 15 other […]

July 12, 2016 - 6 minutesmins - By Dani Bancroft

News and Trends 12 Jul 2016

Which European Biotechs made it to the Billion-Euro Club in 2016?

Europe has a lot of successful Biotech companies, but which of those are worth a billion euros or more? I did a previous version of this article last year and now I explore how these have evolved. Just 9 European Biotech companies (private and public) are worth over one billion right now. Many of these were present last year. For […]

July 12, 2016 - 6 minutesmins - By Philip Hemme

News and Trends 11 Jul 2016

On the way to a ‘Functional’ HIV Cure? Norway Vaccine clears viral load in 88% of Patients

Oslo based Biopharma Bionor has a Phase I results for a HIV vaccine. The vaccine infusion rendered viral presence in 88% of patients undetectable after combination treatments with Celgene‘s enzyme inhibitor, Istodax and standard retroviral drugs. The positive results from the clinical trial REDUC Part B were published in the high impact journal The Lancet HIV. The Norwegian’s proprietary […]

July 11, 2016 - 3 minutesmins - By Dani Bancroft

News and Trends 11 Jul 2016

After Genentech, Roche could acquire another American Billion-dollar Biotech

Roche is rumored to make a move on the California biotech BioMarin. Despite a slightly weakened pipeline, Roche appears undeterred and previous offers were predicted to be around $15Bn. As big as some of the other industry veterans, BioMarin was founded in the 90’s boom in Biotech in San Rafaele, California. The deal itself is entirely based on […]

July 11, 2016 - 2 minutesmins - By Dani Bancroft

News and Trends 11 Jul 2016

Nanobody Phase II Results for Arthritis: Good but not good enough?

Ablynx has shown that its candidate for Rheumatoid arthritis could work as a monotherapy, but whether they can convince AbbVie to stick to the previous $840M deal is still unclear. Ghent-based Ablynx has hooked several big Pharmas with its Nanobody platform, based on the shorter monoclonal antibodies of llamas. One of these is AbbVie (France), which is […]

July 11, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 11 Jul 2016

How to build a Successful Biotech company in Europe with Joern Aldag

Joern Aldag is one of the impressive Biotech leaders in Europe. Hearing him at our Refresh conference made me think of a new type of article we could publish: a detailed summary of the lessons learned from such a very rich career. Here’s the first of such a piece. Aldag was just appointed CEO of […]

July 11, 2016 - 6 minutesmins - By Philip Hemme

News and Trends 9 Jul 2016

Bio-printing Clothes and Darwin’s book ‘On the Origin of Species’ with Bacteria

Simon Park is a professor at the University of Surrey in the UK who created the first book to be ‘printed’ with living bacteria, whereas Suzanne Lee is a New York based designer who uses the same species of bacteria in her clothing designs. This is probably one of the most unusual tributes to Charles Darwin, the English naturalist and geologist […]

July 9, 2016 - 4 minutesmins - By Joachim Eeckhout

News and Trends 8 Jul 2016

Copenhagen-based Pcovery is looking to fight invasive Fungal Infections

After another visit to the United Kingdom, we ‘Brexit’ towards other geographies! We’re crossing the English Channel back to the continent and go further up to Denmark. This week, in Copenhagen, we’re visiting Pcovery, our Biotech of the Week. City: Copenhagen (Denmark) Founded: 2009 Employees: 6 Financial Data: €7.5M Total Raised (as of 12/2015) CEO: Casper Tind Hansen […]

July 8, 2016 - 2 minutesmins - By Joachim Eeckhout

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

French Biotech that makes Drugs faster and cheaper IPO’s for €31M

French Pharma licenses California PD-1 Cancer Antibody for €710M

Europe’s most valuable Biotech just launched 2 new Trials

Unique Natural Killer T-Cell Therapy secures €282M in Japan Deal

How did Helen Lee overcome barriers to HIV Diagnostics in the ‘Real World’?

Which European Biotechs made it to the Billion-Euro Club in 2016?

On the way to a ‘Functional’ HIV Cure? Norway Vaccine clears viral load in 88% of Patients

After Genentech, Roche could acquire another American Billion-dollar Biotech

Nanobody Phase II Results for Arthritis: Good but not good enough?

How to build a Successful Biotech company in Europe with Joern Aldag

Bio-printing Clothes and Darwin’s book ‘On the Origin of Species’ with Bacteria

Copenhagen-based Pcovery is looking to fight invasive Fungal Infections

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!